GEMoaB, Intellia Enter Cellular Immunotherapy Research Pact

GEMoaB, a biopharmaceutical company focused on next-generation immunotherapies for hard-to-treat cancers, has entered into a research collaboration and license agreement with Intellia, a global leader in the field of genome editing treatments.

The companies will conduct joint research to combine GEMoaB's RevCAR technology platform with Intellia's genome editing technologies to discover and develop next-generation allogeneic cellular immunotherapies for hard-to-treat cancers and inflammatory diseases. The companies will focus on immunotherapies directed against a selected number of targets.

GEMoaB will receive payments for each product based on target reservation and selection, achievement of regulatory, clinical and commercial milestones as well as royalties on sales. Intellia will lead the research collaboration, and be responsible for clinical development and commercialization.